Versant Capital Management, Inc Day One Biopharmaceuticals, Inc. Transaction History
Versant Capital Management, Inc
- $710 Million
- Q3 2025
A detailed history of Versant Capital Management, Inc transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Versant Capital Management, Inc holds 604 shares of DAWN stock, worth $5,315. This represents 0.0% of its overall portfolio holdings.
Number of Shares
604
Previous 604
-0.0%
Holding current value
$5,315
Previous $3,000
33.33%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding DAWN
# of Institutions
178Shares Held
70.5MCall Options Held
42.8KPut Options Held
60.3K-
Atlas Venture Life Science Advisors, LLC6.43MShares$56.6 Million10.23% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.18MShares$54.4 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY4.71MShares$41.4 Million0.62% of portfolio
-
Black Rock Inc. New York, NY4.53MShares$39.9 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA3.48MShares$30.6 Million0.01% of portfolio
About Day One Biopharmaceuticals, Inc.
- Ticker DAWN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 73,461,104
- Market Cap $646M
- Description
- Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...